Sterling Capital Management
MPLT icon

Sterling Capital Management’s MapLight Therapeutics MPLT Stock Holding History

Sterling Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.37K Buy
331
+275
+491% +$5.16K ﹤0.01% 3023
2026
Q2 		$2.01K Sell
56
-314
-85% -$9.03K ﹤0.01% 2992
2026
Q1 		$7.52K Sell
370
-149
-29% -$2.66K ﹤0.01% 2523
2025
Q4 		$9.12K Buy
+519
New +$8.7K ﹤0.01% 2656

Other funds holding MPLT

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Market Street Wealth Management Advisors
Market Street Wealth Management Advisors Indianapolis, Indiana $703M AUM 10.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Sterling Capital Management's MPLT Position: Q3 2026 in Review

Sterling Capital Management increased its MapLight Therapeutics (MPLT) stake by 491% in Q3 2026, buying an estimated $5.16K and bringing the position to 331 shares worth $3.37K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Sterling Capital Management first reported a position in MPLT in Q4 2025 and has held it in 4 quarters since. The position peaked at $9.12K in Q4 2025. 25 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.

  • Sterling Capital Management held 331 shares of MapLight Therapeutics worth $3.37K as of Q3 2026.
  • Sterling Capital Management bought 275 MapLight Therapeutics shares in Q3 2026, an estimated $5.16K.
  • MapLight Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3023 holding.
  • Sterling Capital Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Sterling Capital Management's MapLight Therapeutics position peaked at $9.12K in Q4 2025.
  • 25 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.